EDIT - Why Editas Medicine Stock Was Skyrocketing This Week
2025-08-15 07:50:43 ET
Gene-editing company Editas Medicine (NASDAQ: EDIT) was something of an unexpected star on the stock exchange as the trading week came to a close. The small biotech's share price was up by a robust 34% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence , thanks to a well-received quarterly earnings report and business update.
Editas published the earnings release on Tuesday. The clinical-stage biotech earned slightly under $3.6 million in revenue during the period, which was entirely derived from collaboration and other research and development activities. That was, however, well up from the $513,000 in the same quarter last year.
Image source: Getty Images.